Karen Knudsen: Incredibly grateful to have Pfizer’s support of the American Cancer Society National Prostate Cancer Roundtable

Karen Knudsen shared a post by Pfizer on LinkedIn, adding:

“We are incredibly grateful to have Pfizer‘s support of the American Cancer Society National Prostate Cancer Roundtable! Through our ongoing collaboration on this and other initiatives, Pfizer has been a tremendous partner. Together, we are working to address health disparities and end cancer as we know it, for everyone.”

Quoting Pfizer:

“We were proud to join the American Cancer Society (ACS), Prostate Health Education Network, ZERO Prostate Cancer and other leaders across the Oncology community for the launch of the National Prostate Cancer Roundtable, a coalition of organizations dedicated to a shared vision of improving prostate cancer outcomes and survivorship for all through increasing awareness and equitable access to prevention, screening and treatment.

Prostate cancer is the second most common cancer among men in the United States, with about 1 in 8 men facing a diagnosis in their lifetime. Black men are not only more likely to be diagnosed with prostate cancer, but are also twice as likely to die from the disease than other racial or ethnic groups.

At Pfizer, we believe in the power of collaboration and partnership to drive meaningful change. Through our sponsorship of the National Prostate Cancer Roundtable as well as other collaborative efforts with the community, such as our Change the Odds initiative with ACS and support for PHEN’s Prostate Cancer Disparity Rally, we are dedicated to addressing these disparities and improving cancer outcomes for all.”

Source: Karen Knudsen/LinkedIn and Pfizer/LinkedIn

Karen E. Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health.

She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR). She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.